We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




AACC Releases Guidelines on Point-of-Care Testing for Non-Laboratorians

By LabMedica International staff writers
Posted on 14 Sep 2022

Point-of-care testing (POCT), or near-patient testing, is diagnostic testing conducted close to the patient, often by clinical personnel outside of the laboratory. More...

POCT is regularly performed by personnel without a laboratory science degree or credentialing in laboratory medicine. Now, a new guidance document is available for non-laboratorians who are involved in setting up a process or physical space designed to provide testing at or near where patient care is provided.

The guide released by the American Association for Clinical Chemistry (AACC, Washington, DC, USA) presents the challenges to consider when selecting and implementing diagnostic testing. It provides an overview of POCT, including a discussion of the cost-benefit analysis of implementing POCT and the use of POCT in various healthcare settings. The AACC guide presents the challenges to consider when selecting and implementing POCT. It also offers tools to address and manage those challenges and offers solutions to overcome barriers faced in various settings to ensure quality test results that are reliable for patient care.

The AACC guide includes addenda, including glossaries, templates, and forms, to serve as tools in the implementation of POCT. These are for reference use only; individual POCT laboratories may have unique needs. The guide is not meant to be an all-inclusive ‘how to’ set up a POCT laboratory and is to be used as supportive instruction and education to implement good laboratory practices, according to the AACC. The guide is most helpful when used in conjunction with all information provided by the test manufacturer, including the Manufacturer’s Instructions for Use (MIFU) for testing materials, products, and devices that one has selected to provide laboratory testing services to patients.

Related Links:
AACC 


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The updated CRC screening guidance adds a stool RNA test and an updated stool DNA test to the menu of preferred options (image credit: Adobe Stock)

Updated Guidance Prioritizes Stool-Based Colorectal Cancer Screening Tests

Colorectal cancer is the second-leading cause of cancer death in the United States and claimed an estimated 55,000 lives in 2026. Incidence is rising among adults younger than 50, even as overall mortality... Read more

Immunology

view channel
Image: Study design for analysis of monocyte phenotype, function, and metabolism (Gráinne Jameson et al., Journal of Infection (2026). DOI: 10.1016/j.jinf.2026.106755)

Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.